Firmagon Unione Europea - italiano - EMA (European Medicines Agency)

firmagon

ferring pharmaceuticals a/s - degarelix - neoplasie prostatiche - terapia endocrina - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Degarelix Accord Unione Europea - italiano - EMA (European Medicines Agency)

degarelix accord

accord healthcare s.l.u. - degarelix acetate - neoplasie prostatiche - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

FACOVIT COLL 10ML Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

facovit coll 10ml

teofarma srl - testosterone propionato/rubidio ioduro/potassio ioduro/riboflavina - collirio - flac. contagocce collirio 10 ml - other ophthalmologicals